Images Powered by Shutterstock
Avelumab maintenance extends OS in advanced urothelial carcinoma

Avelumab maintenance extends OS in advanced urothelial carcinoma

Avelumab maintenance extends OS in advanced urothelial carcinoma January 12, 2020 Add Topic To Email Alerts Please provide your email address to receive an email when new...

Microscopic Traces of Blood in Urine Linked to Urological Cancer

Microscopic Traces of Blood in Urine Linked to Urological Cancer

NEW YORK (Reuters Health) - Non-visible hematuria (NVH) was associated with bladder cancer (BC), upper tract urothelial carcinoma (UTUC) and kidney cancer (KC) in a systematic...

From Aha! Moment to FDA Approval: The Fascinating Story Behind a New Treatment for Bladder Cancer

From Aha! Moment to FDA Approval: The Fascinating Story Behind a New Treatment for Bladder Cancer

2008 A Cancer Research Collaboration Kicks Off Janssen enters into an exclusive worldwide license and collaboration agreement with Astex Therapeutics Ltd. , an oncology drug...

CTLA-4 Inhibitor Shows Promise in Pretreated Urothelial Cancer

CTLA-4 Inhibitor Shows Promise in Pretreated Urothelial Cancer

In some patients with metastatic urothelial carcinoma for whom standard-of-care platinum-based chemotherapy had failed, single-agent tremelimumab (CP-675,206) provided a durable...

Chronic Pot Use Possibly Linked to Testicular Cancer

Chronic Pot Use Possibly Linked to Testicular Cancer

Chronic marijuana smoking may be linked to the development of testicular germ cell tumor (TGCT), specifically of the nonseminoma histologic subtype, a systematic review and...

ESMO Issues Practice Guidelines Update for Treatment of Bladder Cancer

ESMO Issues Practice Guidelines Update for Treatment of Bladder Cancer

ESMO Issues Practice Guidelines Update for Treatment of Bladder Cancer Suzanne Morris, DVM Published Online: Oct 29,2019 Thomas Powles, MD, MBBS Several novel therapeutics have...

Immunotherapy Added to CT Might Just Work in Bladder Cancer

Immunotherapy Added to CT Might Just Work in Bladder Cancer

BARCELONA, Spain — Immunotherapy added to chemotherapy might just work in advanced bladder cancer: results so far from IMvigor130 show an improvement in progression-free...

Investigational Mitomycin Gel Agents Demonstrate High CR Rates in Bladder Cancer Studies

Investigational Mitomycin Gel Agents Demonstrate High CR Rates in Bladder Cancer Studies

The investigational agent UGN-101 induced a complete response (CR) in 59% of patients with low-grade upper tract urothelial cancer (LG UTUC) in the phase III OLYMPUS trial,...

Warning Stalled Immunotherapy Takeover in Bladder Cancer

Warning Stalled Immunotherapy Takeover in Bladder Cancer

The FDA's May 2018 warning against prescribing immunotherapy alone in bladder cancer patients with low PD-L1 expression quickly reversed the surge in use of these agents as...

Common cold virus could transform bladder cancer treatment

Common cold virus could transform bladder cancer treatment

A novel therapeutic approach that involves the oncolytic virus coxsackievirus showed potential among a small cohort of patients with nonmuscle-invasive bladder cancer, according...

Mount Sinai awarded $1.7 million to study how bladder cancer affects 'natural killer' cells

Mount Sinai awarded $1.7 million to study how bladder cancer affects 'natural killer' cells

The Icahn School of Medicine at Mount Sinai has been awarded nearly $1.7 million in grant funding from the U.S. Department of Defense to study how bladder cancer affects certain...

Molecular and histopathology directed therapy for advanced bladder cancer

Molecular and histopathology directed therapy for advanced bladder cancer

Molecular and histopathology directed therapy for advanced bladder cancer Nature Reviews Urology (2019) | Download Citation Subjects Targeted therapies Abstract Bladder cancer...